ID   PLS-1
AC   CVCL_4U94
SY   PLS1
DR   Wikidata; Q54947581
RX   PubMed=20419128;
RX   PubMed=26373732;
CC   Doubling time: ~1.6 days (PubMed=26373732).
DI   NCIt; C8795; Recurrent undifferentiated pleomorphic sarcoma
DI   ORDO; Orphanet_2023; Undifferentiated pleomorphic sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   80Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 21-03-23; Version: 5
//
RX   PubMed=20419128; DOI=10.1371/journal.pone.0010105; PMCID=PMC2855704;
RA   Lahat, Guy
RA   Zhu, Quan-Sheng
RA   Huang, Kai-Lieh
RA   Wang, Sui-Zhao
RA   Bolshakov, Svetlana V.
RA   Liu, Jeffrey Jue-Hui
RA   Torres, Keila Enitt
RA   Langley, Robert R.
RA   Lazar, Alexander J.F.
RA   Hung, Mien-Chie
RA   Lev, Dina Chelouche
RT   "Vimentin is a novel anti-cancer therapeutic target; insights from in
RT   vitro and in vivo mice xenograft studies.";
RL   PLoS ONE 5:e10105.1-e10105.19(2010).
//
RX   PubMed=26373732; DOI=10.1007/s13277-015-4050-6;
RA   Mersch, Sabrina
RA   Riemer, Jasmin C.
RA   Schlunder, Philipp M.
RA   Ghadimi, Markus P.
RA   Ashmawy, Hany
RA   Mohlendick, Birte
RA   Topp, Stefan A.
RA   Arent, Tanja
RA   Kropil, Patric
RA   Stoecklein, Nikolas H.
RA   Gabbert, Helmut Erich
RA   Knoefel, Wolfram Trudo
RA   Krieg, Andreas
RT   "Peritoneal sarcomatosis: site of origin for the establishment of an
RT   in vitro and in vivo cell line model to study therapeutic resistance
RT   in dedifferentiated liposarcoma.";
RL   Tumor Biol. 37:2341-2351(2016).
//